Latest news with #CONMED
Yahoo
06-08-2025
- Business
- Yahoo
Zimmer Biomet (ZBH) Q2 Earnings: What To Expect
Medical device company Zimmer Biomet (NYSE:ZBH) will be reporting earnings this Thursday before the bell. Here's what you need to know. Zimmer Biomet beat analysts' revenue expectations by 0.7% last quarter, reporting revenues of $1.91 billion, up 1.1% year on year. It was a slower quarter for the company, with a miss of analysts' full-year EPS guidance estimates. Is Zimmer Biomet a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Zimmer Biomet's revenue to grow 5.4% year on year to $2.05 billion, improving from the 3.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.98 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Zimmer Biomet has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.6% on average. Looking at Zimmer Biomet's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. CONMED delivered year-on-year revenue growth of 3.1%, beating analysts' expectations by 1.2%, and iRhythm reported revenues up 26.1%, topping estimates by 7.3%. CONMED traded up 1.8% following the results while iRhythm was also up 17.6%. Read our full analysis of CONMED's results here and iRhythm's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Zimmer Biomet's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $107.79 (compared to the current share price of $92.98). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
29-07-2025
- Business
- Yahoo
CONMED (CNMD) Q2 Earnings: What To Expect
Medical tech company CONMED (NYSE:CNMD) will be announcing earnings results this Wednesday after market close. Here's what to look for. CONMED beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $321.3 million, up 2.9% year on year. It was a very strong quarter for the company, with a solid beat of analysts' full-year EPS guidance estimates and an impressive beat of analysts' EPS estimates. Is CONMED a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting CONMED's revenue to grow 1.9% year on year to $338.3 million, slowing from the 4.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CONMED has missed Wall Street's revenue estimates three times over the last two years. Looking at CONMED's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. CONMED is down 4% during the same time and is heading into earnings with an average analyst price target of $66.60 (compared to the current share price of $50.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-07-2025
- Business
- Yahoo
Needham Downgrades CONMED Corporation (CNMD) to Hold from Buy
CONMED Corporation (NASDAQ:CNMD) is one of the best undervalued medical device stocks to buy now. On June 12, Needham downgraded CONMED Corporation (NASDAQ:CNMD) to Hold from Buy without a price target. Closeup portrait of a surgeon wearing a surgical mask and gown while holding a surgical device. The firm told investors in a research note that CONMED Corporation (NASDAQ:CNMD) is experiencing a drop in its long-term growth rate, primarily attributed to slower AirSeal and Buffalo Filter growth. It believes that slower revenue growth is likely to result in slower earnings growth and more gradual margin improvement for the company. The firm further reasoned that CONMED Corporation's (NASDAQ:CNMD) debt levels restrict its potential to repurchase shares or acquire new growth drivers. It contended that the company's outlook has deteriorated, and the shares are no longer at a discount provided that peer multiples have contracted. CONMED Corp (NASDAQ:CNMD) is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. Healthcare professionals, such as surgeons, use their products in a range of specialties, such as general surgery, orthopedics, thoracic surgery, gynecology, and gastroenterology. The company's product line comprises general surgery and orthopedic surgery. General surgery comprises endo-mechanical instrumentation primarily used for minimally invasive gastrointestinal and laparoscopic procedures. The orthopedic surgery product line comprises lower extremities, sports medicine implants and instrumentation, specialty-powered surgical instruments, and more. While we acknowledge the potential of CNMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
11-07-2025
- Business
- Yahoo
Lantheus, ICU Medical, Haemonetics, CONMED, and Astrana Health Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Medical Devices & Supplies - Imaging, Diagnostics company Lantheus (NASDAQ:LNTH) fell 3.1%. Is now the time to buy Lantheus? Access our full analysis report here, it's free. Medical Devices & Supplies - Cardiology, Neurology, Vascular company ICU Medical (NASDAQ:ICUI) fell 3.3%. Is now the time to buy ICU Medical? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company Haemonetics (NYSE:HAE) fell 3.4%. Is now the time to buy Haemonetics? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Diversified company CONMED (NYSE:CNMD) fell 3.7%. Is now the time to buy CONMED? Access our full analysis report here, it's free. Healthcare Technology for Providers company Astrana Health (NASDAQ:ASTH) fell 3.3%. Is now the time to buy Astrana Health? Access our full analysis report here, it's free. CONMED's shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. CONMED is down 23.3% since the beginning of the year, and at $51.67 per share, it is trading 33.4% below its 52-week high of $77.54 from November 2024. Investors who bought $1,000 worth of CONMED's shares 5 years ago would now be looking at an investment worth $708.88. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Business Wire
07-07-2025
- Business
- Business Wire
Martha Aronson to Step Down from CONMED Board of Directors Following Appointment as President and Chief Executive Officer
BUSINESS WIRE)-- CONMED Corporation (NYSE: CNMD) today announced that Martha Aronson will be stepping down from the company's Board of Directors to assume the role of President and Chief Executive Officer at Merit Medical, a global leader in the development, manufacture and distribution of proprietary medical devices. Mrs. Aronson's resignation from the Board will be effective July 7, 2025, as she transitions to her new leadership responsibilities. 'We are sincerely grateful to Martha for her years of dedicated service to CONMED,' said Pat Beyer, President and Chief Executive Officer of CONMED. 'Her guidance and expertise have been invaluable to our Board and to me personally as I stepped into the CEO role. We will miss her thoughtful leadership and wish her continued success in this exciting next chapter.' LaVerne Council, Chair of the Board of Directors, added, 'On behalf of the entire Board, I want to thank Martha for her outstanding contributions to CONMED. Her strategic insight and unwavering commitment to excellence have helped shape the company's direction and success. We wish her all the best as she takes on this new opportunity as President and CEO of Merit Medical.' Ms. Aronson joined the CONMED Board in February 2016 and served in various leadership capacities, including as Chair of the Board. Her tenure has been marked by a focus on strategic growth, governance excellence, and a deep commitment to the company's mission and values. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit Forward-Looking Statements This press release may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2024, listed under the heading Forward-Looking Statements in the Company's most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
